Asset
PAMREVLUMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01181245 | phase1 | completed | 2008-12-01 | 2014-05-01 | Kyntra Bio | A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer |
| NCT01217632 | phase2 | terminated | 2010-08-01 | 2015-06-01 | Kyntra Bio | A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection |
| NCT02210559 | phase1_2 | completed | 2014-07-31 | 2021-12-15 | Kyntra Bio | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer |
| NCT00754143 | phase1 | completed | 2008-03-01 | 2009-12-01 | Kyntra Bio | Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy |
| NCT00782561 | phase1 | terminated | 2008-04-01 | 2009-06-18 | Kyntra Bio | Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) |
FDA applications (0)
This company has no applications containing this asset.